Porous PLGA microspheres loaded with PTH1-34 peptide for long-term treatment of OA
The system demonstrates prominent clinical translation advantages: (1) Innovative utilization of FDA-approved PLGA carrier combined with membrane emulsification technique ensures precise size control and standardized production; (2) Localized delivery strategy achieves targeted retention within articular cavity, validated by animal studies showing no systemic exposure risks; (3) Standardized preparation process demonstrates the feasibility of industrial-scale production.
Authors
- Wang Diaodiao
- Gang Zhang (ORCID: https://orcid.org/0000-0002-0195-1209)
- Peng Ye (ORCID: https://orcid.org/0000-0002-4182-4183)
- Yubo Liu (ORCID: https://orcid.org/0000-0003-0645-0822)
- Zhuang Tian (ORCID: https://orcid.org/0009-0002-2200-278X)
- Qi Yao (ORCID: https://orcid.org/0000-0001-5408-9838)
- Yuyang Sun
- Wenqiang Sun
- Tang Miaotian
- Ren Pengcheng
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Nankai University (CN)
- Beijing Forestry University (CN)
- Peking University People's Hospital (CN)
- Institute of Process Engineering (CN)
- Beijing Shijitan Hospital (CN)
Publication Details
- Journal
- Journal of Orthopaedic Translation
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1016/j.jot.2025.05.003
- Citations
- 6
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 10.01
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality